



PRESS RELEASE

For Immediate Release:

Contact:

Miles Tyrer
American Radiosurgery
Ph: (858) 451-6173
Fax: (858) 487-0662
info@americanradiosurgery.net
www.americanradiosurgery.net

University of Debrecen, Hungary Treats Over 2,500 Patients Using American Radiosurgery's Rotating Gamma System® RGS Vertex360®

San Diego, CA, August 1, 2012 - American Radiosurgery, Inc., today announced that the radiosurgery team from the University of Debrecen, Hungary has successfully treated over 2,500 patients using the RGS Vertex360.

The RGS Vertex360 was installed at the University of Debrecen in 2007 and the first patient was treated in September of that year. The RGS Vertex360 is a computer-controlled radiation device that uses cobalt-60 to non-invasively treat brain tumors with pinpoint accuracy and precision. Patients receive treatment and return home on the same day, thereby avoiding the complications of open skull surgery and the extended recovery period associated with such procedures.

"We are exceptionally delighted to have achieved such an expanded base of successful patient outcomes using the RGS Vertex360," stated Professor Laszlo Bognar, Chairman of the Neurosurgery Department at the University of Debrecen. "American Radiosurgery has been an outstanding corporate partner in our radiosurgery program," Professor Bognar went on to add.

John Clark, Chairman & CEO of American Radiosurgery, Inc. commented, "The number of successful patient treatments at the University validates the effectiveness of our core technology. The RGS Vertex360 continues to demonstrate its reliability in providing neurosurgeons with advanced and cost effective radiosurgery capabilities".

American Radiosurgery, Inc., is based in San Diego, California and is a neurosurgical radiosurgical device company providing advanced technology for the non-invasive treatment of brain tumors and other brain disease entities.

###

Statements in this news release may contain forward-looking statements within the meaning of Section 27A of the U.S. Securities Act of 1993 and Section 21E of the Securities and Exchange Act of 1934. Such statements may involve various risks and uncertainties, some of which may be discussed in the Company's most recent shareholder letter. There is no assurance any new products can be cleared for sale by the FDA or successfully commercialized or any forward-looking statements will prove accurate, as actual results and future events could differ materially from those presently anticipated.